

1.4E+06
1.2E+06
1.0E+06
0.8E+05
6.0E+05
4.0E+05
2.0E+05
0.0E+00
RLU/μg Protein
sc/LipA
sc/LipA-HoKC

FIG. 1



RLU/μg protein
2.5E+05
2.0E+05
1.5E+05
1.0E+05
5.0E+04
0.0E+00
sc/LipA-HoKC
sc/LipG-HoKC
sc/LipD-HoKC
LipA-HoKC
LipG-HoKC
LipD-HoKC
sc/LipA
sc/LipG
sc/LipD
LipA
LipG
LipD
(LipA-HoKC/DNA)'PSchol-GAL
(LipG-HoKC/DNA)'PSchol-GAL
(LipD-HoKC/DNA)'PSchol-GAL
(LipA/DNA)'PSchol-GAL
(LipG/DNA)'PSchol-GAL
(LipD/DNA)'PSchol-GAL
Lip A-L-37pA
Lip G-L-37pA
Lip D-L-37pA
sc
GAL
L-37pA
1 2 3 4 5 6 7 5 9 10 11 12 13 14 15 16 17 18 19 20 21

FIG.2




FIG. 3



pAGVec
pAG410
pAGVec
pAG410
85
NS5B (p68)
41.7
32.1
NS3 (p70)
NS5A (p58)
NS4B (p27)
GAPDH

FIG.4




FIG.5



Marker
Pos.
Neg.
pAG410
M3
M2
M1
scL-pAG410
M3
M2
M1
scL-Vector
M3
M2
M1

FIG.6



rW-NS3 Titers In Mouse Ovaries
p=0.407
p=0.005
p=0.002
Virus Titers (pfu/ovary)
1.E+07
1.E+06
1.E+07
1.E+04
1.E+03
1.E+02
1.E+01
PBS
scL-HCV/
scL-IL-12
scL-Vec/
scL-IL-12
naked HCV/
naked IL-12

FIG. 7



Ch1601 Vaccination & Infection
V
C
P/N an1-HVR1(1:640)
log10 RNA copies/ml
30
25
20
15
10
5
0
7
6
5
4
3
2
1
0
-682
0
4
8
12
18
20
24
28

FIG.8A



Ch1587 Vaccination & Rechallenge
V
V
C
P/N an1-HVR1(1:640)
log10 RNA copies/ml
30
25
20
15
10
5
0
7
6
5
4
3
2
1
0
-20
-18
-12
-8
-4
0
4
8
12
18
Week pJ.
V=Vaccination C=Challenge

FIG.8B




FIG.9A




FIG.9B




FIG.9C




FIG.10A




FIG.10B




FIG.10C




FIG.11A




FIG.11B




FIG.11C




FIG.12A




FIG.12B




FIG.12C



HCV Titer Post-Virus Challenge
RNA Titer Log10 (IU/ml)
1e+6
1e+5
1e+4
1e+3
Weeks
0 1 2 3 4 5 6 7 8
Control
(Ch0257)
0 1 2 3 4 5 6 7 8
Vac.2
(Ch1611)
0 1 2 3 4 5 6 7 8
Vac.1
(Ch6407)

FIG.13



ALT Levels Post-HCV Virus Challenge
Vaccinated 1 (Ch6407)
Vaccinated 2 (Ch1611)
Control (Ch0257)
ALT (IU/ml)
100
200
300
400
500
1
2
3
4
5
6
Weeks Post Challenge

FIG.14



T-Cell Proliferation
GFP
NS3
NS5A
NS5B
Relative Proliferation Levels
25
20
15
10
5
0
pre
rW
wk2
wk3
wk14
wk15
Post rW
Time Point

FIG. 15




FIG.16A

FIG.16B

FIG.16C




CTL

FIG.17A



LUC

FIG.17B



scLLUC

FIG.17C

SEQUENCE LISTING

<110> Georgetown University

<120> Methods for Generating Immune Response Using Cationic-Liposome-Mediated Nucleic Acid Delivery

<130> SG1545A

<140> To Be Assigned
<141> Herewith

<150> US 60/929,685
<151> 2007-07-09

<160> 1

<170> PatentIn version 3.3

<210> 1
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically synthesized - HoKC

<400> 1

Lys Lys His Lys Lys Lys Lys His Lys Lys Lys Lys His Lys Lys Lys
1 5 10 15

Lys His Lys Lys Lys Lys His Lys Lys Lys Lys His Lys Lys Cys
20 25 30